|
gptkbp:instance_of
|
gptkb:skincare_product
|
|
gptkbp:activities
|
viscosupplementation
|
|
gptkbp:appointed_by
|
injection
|
|
gptkbp:approves
|
gptkb:2004
gptkb:FDA
|
|
gptkbp:availability
|
prescription only
|
|
gptkbp:clinical_trial
|
Phase III
positive efficacy
safety established
joint lubrication
|
|
gptkbp:contains
|
hyaluronic acid
|
|
gptkbp:contraindication
|
infection at injection site
hypersensitivity to hyaluronic acid
|
|
gptkbp:dosage_form
|
intra-articular injection
|
|
gptkbp:duration
|
up to 6 months
once a week for 3 weeks
|
|
gptkbp:education
|
informed consent required
|
|
gptkbp:formulation
|
sterile solution
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Euflexxa
|
|
gptkbp:indication
|
knee pain
|
|
gptkbp:ingredients
|
hyaluronic acid
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_effective_against
|
reduces pain
improves joint function
|
|
gptkbp:is_used_for
|
osteoarthritis
|
|
gptkbp:manager
|
intra-articular
|
|
gptkbp:manufacturer
|
gptkb:Ferring_Pharmaceuticals
|
|
gptkbp:market
|
gptkb:USA
gptkb:EU
gptkb:Native_American_tribe
ongoing
|
|
gptkbp:marketed_as
|
gptkb:Ferring_Pharmaceuticals
|
|
gptkbp:packaging
|
single-use syringe
|
|
gptkbp:population
|
adults
|
|
gptkbp:price
|
varies by region
|
|
gptkbp:products
|
gptkb:Synvisc
gptkb:Orthovisc
gptkb:Supartz
Durolane
|
|
gptkbp:provides_information_on
|
gptkb:American_Academy_of_Orthopaedic_Surgeons
European Society of Musculoskeletal Radiology
|
|
gptkbp:research
|
randomized controlled trials
|
|
gptkbp:safety_features
|
generally well tolerated
|
|
gptkbp:side_effect
|
allergic reaction
bruising
swelling
redness
itching
pain at injection site
infection risk
joint swelling
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:treatment
|
pain relief
patient satisfaction
improved mobility
reduced need for surgery
|
|
gptkbp:bfsParent
|
gptkb:Synvisc
|
|
gptkbp:bfsLayer
|
5
|